Neumora Therapeutics appoints Paul Berns as Chairman & CEO, Gosebruch exits

Neumora Therapeutics, Inc.

Henry Gosebruch separates as CEO; receives 12-month base salary, 2025 target bonus, 18-month COBRA, 2024 bonus, and 12-month option exercise period.
Paul L. Berns appointed Chairman & CEO with $700,000 base salary and 60% annual bonus target, effective Feb 14, 2025.
Berns receives option to purchase 2,000,000 shares vesting over 4 years (25% after 1 year, monthly thereafter).
Berns severance: 12 months salary + bonus (non-CIC); 24 months salary + 2x bonus + equity acceleration (CIC-related).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Henry Gosebruch

President and Chief Executive Officer

NMRA · Neumora Therapeutics, Inc.

Effective: 2025-02-14
Successor: Paul L. Berns
Filed: February 21, 2025, 6:59 PM ET

the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer

Appointed

Paul L. Berns

Chairman and Chief Executive Officer

NMRA · Neumora Therapeutics, Inc.

Effective: 2025-02-14
Filed: February 21, 2025, 6:59 PM ET

an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Henry Gosebruch departed as President and Chief Executive Officer at Neumora Therapeutics, Inc..

Action: separated
Role: President and Chief Executive Officer

Exact text from the filing

the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul L. Berns was appointed as Chairman and Chief Executive Officer at Neumora Therapeutics, Inc..

Action: appointed
Role: Chairman and Chief Executive Officer

Exact text from the filing

an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer

View on SEC.gov

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-031974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.